| Nov 14 |
The Oncology Bet Is Already Paying Off For Pfizer
|
| Nov 12 |
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
|
| Oct 22 |
Mainz Biomed restructured operations, implemented cost reductions
|
| Oct 21 |
Mainz Biomed B.V. GAAP EPS of -$0.49, revenue of $520.77M
|
| Oct 21 |
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
|
| Oct 10 |
Mainz Biomed Secures Additional $1.5M Funding
|
| Oct 8 |
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
|
| Oct 1 |
The Covid Era Tech Promises To Reinvent Cancer Treatment
|
| Oct 1 |
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
|
| Sep 20 |
Pfizer Advances On Its Cancer Journey
|
